CD8A and neoplasm: PD-1 therapy-driven T cell proliferation is not uniform across different T cell subsets, as researchers found that Epstein–Barr virus-specific CD8+ T cells exhibit a diminished response to PD-1 therapy, indicating that the responsive cells might be specific to the tumor (32).